Circulating microRNA group for early detection of breast cancer and method thereof

• Main Authors: BOANDERS MARK H, ZOU RUIYANG, ZHOU LIHAN, CHENG HE, LIN XIUYU, TOO HENG-PHON
• Format: Patent
• Language: Chinese; English
• Published: 14.05.2024
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; COMPOSITIONS THEREOF; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; CULTURE MEDIA; ENZYMOLOGY; INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTEDFOR SPECIFIC APPLICATION FIELDS; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; PHYSICS; PROCESSES OF PREPARING SUCH COMPOSITIONS; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPIRITS; VINEGAR; WINE

Disclosed herein is a method for determining whether a subject suffers from or is at risk of developing breast cancer, wherein the method comprises detecting differential expression levels of at least two or more miRNA markers from a biological sample, preferably in serum. Specifically, in a serum sample from a breast cancer case, miR-133a-3p, miR-497-5p, miR-24-3p, and miR-125b-5p are up-regulated, while miR-377-3p, miR-374c-5p, miR-324-5p, and miR-19b-3p are down-regulated, as compared to a non-cancer control. 本文公开了一种用于确定受试者是否罹患乳腺癌或是否处于发展乳腺癌的风险中的方法，其中所述方法包括检测来自生物样品、优选血清中的至少两个或更多个miRNA标志物的差异表达水平。具体地，与非癌症对照相比，在来自乳腺癌病例的血清样品中，miR-133a-3p、miR-497-5p、miR-24-3p和miR-125b-5p被上调，而miR-377-3p、miR-374c-5p、miR-324-5p和miR-19b-3p被下调。